2020-09-08 23.57.33.jpg
2021.01_edited.jpg

COVID-19

Many regard the coronavirus pandemic as the worst global crisis since World War II. 

Manufacturing billions of coronavirus vaccines in a short time will be the top priority worldwide.

 

ContiVir's technologies have the potential to help with this monumental challenge.

ContiVir's platform for COVID-19 vaccine candidates

Our technology platform has been successfully used for the production of an in-house developed COVID-19 vaccine candidate, demonstrating its potential for tackling the current need for fast, efficient and fully scalable vaccine manufacturing technologies.

Most of the available literature on the production of COVID-19 virus based vaccines reports production in adherent cells with serum-containing media. This approach severely limits its scale-up potential, which is of particular concern considering the billions of vaccine doses required.

Our in-house developed COVID-19 vaccine candidate is based on a non-infectious virus-like-particle (VLP) that resembles the morphology and structure of the SARS-CoV-2 particles but does not contain any of its infective genetic material, thus rendering it extremely safe to produce and handle. These VLPs can be produced in any Biosafety level 1 facility.

Our technologies allowed us to manufacture these VLPs using mammalian suspension cells in chemically-defined cell culture medium, a critical aspect that renders our production process fully scalable for industrial manufacturing. Afterwards, we purified the VLPs with our innovative membrane-based SXC technology, which uses a universal recipe for virus particles and enables much faster processes.

scma_sucrose_dil_grid1_4_02.tiff

Electron microscopy picture of our purified VLPs obtained with our SXC technology.

We have also used our SXC technology for the purification of inactivated SARS-CoV-2 particles:

CO14_dial300_pta_9 copy.jpg

Electron microscopy picture of inactivated SARS-CoV-2 particles purified with our SXC technology.

Production of COVID-19 vaccines

The World Health Organization (WHO) periodically updates a Draft landscape of COVID-19 candidate vaccines.

ContiVir's Technologies can be used to efficiently manufacture virus, virus vector-based, and VLP-based coronavirus vaccine candidates. Encapsulated nucleic acids can also be purified with our SXC technology.

Candidates in blue can be produced and purified with our platform

20210223_WHO_COVID_Vaccine_Candidates_EN

Thus, our manufacturing platform offers a fully scalable solution for a wide range of vaccine candidates currently under development.

We are offering lab-scale devices (a single-use tubular reactor kit and a single-use purification kit) to selected coronavirus researchers who are working with one of the above-mentioned approaches and that require research-grade and pre-clinical material to evaluate the effectiveness of their vaccine candidates. 

Contact us for more information.